The latest market price and trend analysis of mirikizumab in 2025

Mirikizumab (Mirikizumab), as a new type of immunomodulatory monoclonal antibody, is mainly used to treat moderately to severely active ulcerative colitis and Crohn's disease. In recent years, it has gradually gained attention in the global market. As of2025, militizumab has not been officially approved for marketing in mainland China, and domestic patients need to purchase the drug through overseas channels. This has also led to patients facing higher cost pressure and certain difficulty in purchasing the drug.

In the international market, the European version of Militizumab's original drug sells at a higher price. A box of injections with a specification of 300mg/15ml costs about more than 10,000 yuan. The high price is mainly due to factors such as the research and development costs of its innovative biological agents, complex production processes, and patent protection. In addition, biological preparations are generally difficult to produce and have harsh storage and transportation conditions, which further promotes the increase in market prices.

In the next few years, as more countries and regions gradually approve the marketing of milizumab, the market competition for this drug is expected to gradually intensify. The development and launch of generic biosimilars (biosimilars) will be a key factor affecting price trends. The emergence of generic drugs is expected to reduce the overall market price to a certain extent and promote wider popularization and patient accessibility of drugs. At the same time, with the advancement of technology and the expansion of production scale, production costs are expected to further decline, pushing prices to become more reasonable.

Taken together, the market price of militizumab in2025 will still be at a high level. In the short term, patients will rely on imported original drugs, which will result in higher costs. However, with policy support, the gradual entry of biosimilar drugs, and the acceleration of localization, its price is expected to show a downward trend in the next few years, benefiting more patients. The advancement of domestic drug approval and medical insurance inclusion will also greatly improve patients’ financial burden and treatment experience.

Reference materials:https://www.drugs.com/